126 related articles for article (PubMed ID: 12966895)
1. [Development of mucosal influenza inactivated vaccines].
Gendon IuZ
Zh Mikrobiol Epidemiol Immunobiol; 2003; (4):110-7. PubMed ID: 12966895
[TBL] [Abstract][Full Text] [Related]
2. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
Tamura SI; Kurata T
Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses.
Sjölander S; Drane D; Davis R; Beezum L; Pearse M; Cox J
Vaccine; 2001 Jul; 19(28-29):4072-80. PubMed ID: 11427284
[TBL] [Abstract][Full Text] [Related]
4. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.
Ugozzoli M; Santos G; Donnelly J; O'Hagan DT
J Infect Dis; 2001 Jan; 183(2):351-354. PubMed ID: 11110644
[TBL] [Abstract][Full Text] [Related]
5. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
6. Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.
Sano K; Ainai A; Suzuki T; Hasegawa H
Expert Rev Vaccines; 2018 Aug; 17(8):687-696. PubMed ID: 30092690
[TBL] [Abstract][Full Text] [Related]
7. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
Lambkin-Williams R; Gelder C; Broughton R; Mallett CP; Gilbert AS; Mann A; He D; Oxford JS; Burt D
PLoS One; 2016; 11(12):e0163089. PubMed ID: 28005959
[TBL] [Abstract][Full Text] [Related]
8. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
[TBL] [Abstract][Full Text] [Related]
9. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization.
Chen D; Periwal SB; Larrivee K; Zuleger C; Erickson CA; Endres RL; Payne LG
J Virol; 2001 Sep; 75(17):7956-65. PubMed ID: 11483740
[TBL] [Abstract][Full Text] [Related]
10. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
11. Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate.
Ainai A; Suzuki T; Tamura SI; Hasegawa H
Viral Immunol; 2017; 30(6):451-462. PubMed ID: 28650274
[TBL] [Abstract][Full Text] [Related]
12. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.
Burt D; Mallett C; Plante M; Zimmermann J; Torossian K; Fries L
Expert Rev Vaccines; 2011 Mar; 10(3):365-75. PubMed ID: 21434804
[TBL] [Abstract][Full Text] [Related]
13. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
Wu H; Bao Y; Wang X; Zhou D; Wu W
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
[TBL] [Abstract][Full Text] [Related]
14. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
15. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
16. Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly.
Muszkat M; Friedman G; Schein MH; Naveh P; Greenbaum E; Schlesinger M; Zakay-Rones Z; Yehuda AB
Vaccine; 2000 Feb; 18(16):1696-9. PubMed ID: 10689151
[TBL] [Abstract][Full Text] [Related]
17. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
18. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
[TBL] [Abstract][Full Text] [Related]
19. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits.
Dehghan S; Kheiri MT; Abnous K; Eskandari M; Tafaghodi M
Microb Pathog; 2018 Feb; 115():74-85. PubMed ID: 29223454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
